Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 14, Issue 24, Pages 2462-2479Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161208785777469
Keywords
conotoxins; Conus peptides; conopeptides; drug discovery; preclinical development
Categories
Funding
- NIH Program Project [GM 48677, R21 NS055845]
Ask authors/readers for more resources
Over two decades of research on venom peptides derived from cone snails (conopeptides or conotoxins) has led to several compounds that have reached human clinical trials, most of them for treatement of pain. Remarkably, none of the conopeptides in clinical development mediate analgesia through the opioid receptors, underlying the diverse and novel neuropharmacology evolved by Conus snails. These predatory animals produce an estimated similar to 100,000 distinct conotoxins, a vast majority yet to be discovered and characterized. The conopeptides studied to-date in animal models, have exhibited antinociceptive, antiepileptic, neuroprotective or cardioprotective activities. Screening results also suggest applications of conotoxins in cancer, neuromuscular and psychiatric disorders. Additional potentially important applications of conotoxin research are the discovery and validation of new therapeutic targets, also defining novel binding sites on already validated molecular targets. As the structural and functional diversity of conotoxins is being investigated, the Conus venoms continue to surprise with the plethora of neuropharmacological compounds and potential new therapeutics. This review summarizes recent efforts in the discovery of conopeptides, and their preclinical and clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available